Abstract 6813: Immunosuppressive monocytes suppress CART19 functions through modulation of the IL-1 pathway
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Research"
DOI: 10.1158/1538-7445.am2024-6813
Abstract: CD19-directed chimeric antigen receptor T (CART19) cell therapy has shown remarkable outcomes in B cell malignancies and was FDA approved in multiple indications, but durable remissions are limited to ~40%. Inhibitory myeloid cells in the… read more here.
Keywords: jeko; jeko cart19; like macrophages; cell ... See more keywords
Repurposing of the Iron Chelator Deferasirox to Overcome Venetoclax Resistance in Mantle Cell Lymphoma Via Downregulation of MCL1
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-202600
Abstract: Mantle cell lymphoma (MCL) is a difficult to treat B-cell malignancy characterized by cyclin D1 (CD1) overexpression and deregulated AKT, NFκB, MAPK, B-cell receptor and BCL2 pathways. Breakthrough treatments such as BTK inhibitors present clinical… read more here.
Keywords: resistance; mcl1; jeko; cell ... See more keywords